The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | BH3 mimetics as potential treatment for AML
Donia Moujalled, PhD, from the Australian Center for Blood Diseases, Melbourne, Australia, guides us through her team’s investigation on using BH3 mimetics to target the Bcl2 family of pro-survival proteins with the aim of treating acute myeloid leukemia (AML). She describes the differences in efficacies of using Bcl2-targeted and MCL1-targeted BH3 mimetics as either monotherapy or in combination and mentions the promising results, namely improved survival, obtained from murine models of AML which were treated with this dual regimen. With the goal of achieving a chemotherapy-free treatment option for AML patients, she believes that this dual regimen may potentially become an alternative to chemotherapy in the treatment of AML. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
